Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Measurement of proliferative responses of cultured lymphocytes.

Muul LM, Heine G, Silvin C, James SP, Candotti F, Radbruch A, Worm M.

Curr Protoc Immunol. 2011 Aug;Chapter 7:Unit7.10. doi: 10.1002/0471142735.im0710s94.

PMID:
21809319
2.

Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants.

Davis BR, Yan Q, Bui JH, Felix K, Moratto D, Muul LM, Prokopishyn NL, Blaese RM, Candotti F.

Clin Immunol. 2010 Apr;135(1):72-83. doi: 10.1016/j.clim.2009.12.011. Epub 2010 Feb 2.

PMID:
20123155
3.

Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii.

Watford WT, Hissong BD, Durant LR, Yamane H, Muul LM, Kanno Y, Tato CM, Ramos HL, Berger AE, Mielke L, Pesu M, Solomon B, Frucht DM, Paul WE, Sher A, Jankovic D, Tsichlis PN, O'Shea JJ.

J Exp Med. 2008 Nov 24;205(12):2803-12. doi: 10.1084/jem.20081461. Epub 2008 Nov 10.

4.

Measurement of proliferative responses of cultured lymphocytes.

Muul LM, Silvin C, James SP, Candotti F.

Curr Protoc Immunol. 2008 Aug;Chapter 7:Unit 7.10.1-7.10.24. doi: 10.1002/0471142735.im0710s82.

PMID:
18729064
5.

Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome.

Davis BR, Dicola MJ, Prokopishyn NL, Rosenberg JB, Moratto D, Muul LM, Candotti F, Michael Blaese R.

Blood. 2008 May 15;111(10):5064-7. doi: 10.1182/blood-2007-06-095299. Epub 2008 Mar 10.

6.

Immune responses to gene-modified T cells.

Muul LM, Candotti F.

Curr Gene Ther. 2007 Oct;7(5):361-8. Review.

PMID:
17979682
7.

Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans.

Sakamoto N, Tsuji K, Muul LM, Lawler AM, Petricoin EF, Candotti F, Metcalf JA, Tavel JA, Lane HC, Urba WJ, Fox BA, Varki A, Lunney JK, Rosenberg AS.

Blood. 2007 Jul 15;110(2):501-8. Epub 2007 Mar 29.

8.

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F.

Blood. 2003 Apr 1;101(7):2563-9. Epub 2002 Nov 27.

PMID:
12456496
9.

Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy.

Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM.

Hum Gene Ther. 2002 Sep 1;13(13):1605-10.

PMID:
12228015
10.

Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy.

Otsu M, Hershfield MS, Tuschong LM, Muul LM, Onodera M, Ariga T, Sakiyama Y, Candotti F.

Hum Gene Ther. 2002 Feb 10;13(3):425-32.

PMID:
11860709
11.

Unexpected and variable phenotypes in a family with JAK3 deficiency.

Frucht DM, Gadina M, Jagadeesh GJ, Aksentijevich I, Takada K, Bleesing JJ, Nelson J, Muul LM, Perham G, Morgan G, Gerritsen EJ, Schumacher RF, Mella P, Veys PA, Fleisher TA, Kaminski ER, Notarangelo LD, O'Shea JJ, Candotti F.

Genes Immun. 2001 Dec;2(8):422-32.

12.

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH.

Nat Med. 1997 Dec;3(12):1354-61.

PMID:
9396605
13.

High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7739-43.

14.

The role of mucosal immunity in development of an acquired immunodeficiency syndrome (AIDS) vaccine: workshop summary.

Muul LM, Glass MJ, Wescott SL, Burkhardt AL, Koff WC, Strober WG.

Reg Immunol. 1989 May-Jun;2(3):188-92. Review.

PMID:
2701579
15.

Morphology of interleukin-2-stimulated human peripheral blood mononuclear effector cells killing glioma-derived tumor cells in vitro.

Hook GR, Greenwood MA, Barba D, Ikejiri B, Chen SN, Oldfield EH, Weber RJ, Muul LM.

J Natl Cancer Inst. 1988 Apr 6;80(3):171-7.

PMID:
3258038
16.

Technical aspects of lymphokine-activated killer cell production.

Carter CS, Leitman SF, Cullis H, Muul LM, Nason-Burchenal K, Rosenberg SA, Klein HG.

J Clin Apher. 1988;4(2-3):113-7.

PMID:
3397372
17.
18.

Studies of serum-free culture medium in the generation of lymphokine activated killer cells.

Muul LM, Nason-Burchenal K, Hyatt C, Schwarz S, Slavin D, Director EP, Rosenberg SA.

J Immunol Methods. 1987 Dec 24;105(2):183-92.

PMID:
3693906
19.

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Topalian SL, Muul LM, Solomon D, Rosenberg SA.

J Immunol Methods. 1987 Aug 24;102(1):127-41.

PMID:
3305708
20.

Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.

Muul LM, Nason-Burchenal K, Carter CS, Cullis H, Slavin D, Hyatt C, Director EP, Leitman SF, Klein HG, Rosenberg SA.

J Immunol Methods. 1987 Aug 3;101(2):171-81.

PMID:
3611795
21.

Use of a continuous-flow cell separator in density gradient isolation of lymphocytes.

Carter CS, Leitman SF, Cullis H, Muul LM, Nason-Burchenal K, Rosenberg SA, Klein HG.

Transfusion. 1987 Jul-Aug;27(4):362-5.

PMID:
3603668
22.

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.

N Engl J Med. 1987 Apr 9;316(15):889-97.

PMID:
3493432
23.

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

Muul LM, Spiess PJ, Director EP, Rosenberg SA.

J Immunol. 1987 Feb 1;138(3):989-95.

PMID:
3100623
24.

Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.

Skibber JM, Lotze MT, Muul LM, Uppenkamp IK, Ross W, Rosenberg SA.

Nat Immun Cell Growth Regul. 1987;6(6):291-305.

PMID:
2896297
25.

A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C.

Surgery. 1986 Aug;100(2):262-72.

PMID:
3526604
26.

Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.

Muul LM, Director EP, Hyatt CL, Rosenberg SA.

J Immunol Methods. 1986 Apr 17;88(2):265-75.

PMID:
3485692
27.

Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived cells in vitro.

Oberc-Greenwood MA, Muul LM, Gately MK, Kornblith PL, Smith BH.

J Neurooncol. 1986;3(4):387-96.

PMID:
2420943
28.

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al.

N Engl J Med. 1985 Dec 5;313(23):1485-92.

PMID:
3903508
30.

In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack.

Gately CL, Muul LM, Greenwood MA, Papazoglou S, Dick SJ, Kornblith PL, Smith BH, Gately MK.

J Immunol. 1984 Dec;133(6):3387-95.

PMID:
6238097
32.

Polyclonal activation of the murine immune system by an antibody to IgD. III. Ontogeny.

Muul LM, Mond JJ, Finkelman FD.

Eur J Immunol. 1983 Nov;13(11):900-5.

PMID:
6605861
33.
34.
35.

Stimulation of the murine immune system by anti-IgD antibodies: a polyclonal model of B-lymphocyte activation by a thymus dependent antigen.

Finkelman FD, Muul LM, Yaffe L, Scher I, Mond JJ, Kessler SW, Ryan J, Kung JT, Metcalf ES.

Ann N Y Acad Sci. 1982;399:316-28. No abstract available.

PMID:
6984615
36.

Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells.

Broder S, Uchiyama T, Muul LM, Goldman C, Sharrow S, Poplack DG, Waldmann TA.

N Engl J Med. 1981 Jun 4;304(23):1382-7.

PMID:
6453293

Supplemental Content

Support Center